Skip to main content

TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis A phase 2 trial has demonstrated the efficacy of secukinuma

Jun 27, 2023 4:00 pm
Social Author Name
Dr. John Cush
Tweet Content
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA). https://t.co/rDZSQa6wCt https://t.co/WoqK8cpfxC
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×